N/A
Completed N=992
Seroprevalence of SARS-Cov-2 Antibodies in Children
COVID · Corona Virus Infection · Multisystem Inflammatory Syndrome in Children
Source: ClinicalTrials.gov NCT04347408 ↗
Enrolled (actual)
992
Serious AEs
—
Results posted
Aug 2021
Primary outcomePrimary: Immunoglobulins (G and M) to SARS-Cov2 in Plasma — 4.86; 65.32; 64.17 Titres
Summary
It is unknown what proportion of healthy children have been exposed to SARS-Cov-2 and how many have antibodies. The aim of this study is to follow a cohort of healthy children over six months and measure their antibodies to SARS-CoV-2.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Immunoglobulins (G and M) to SARS-Cov2 in Plasma |
4.86; 65.32; 64.17 | — |
| SECONDARY Echocardiogram Ejection Fraction |
— | — |
| SECONDARY High-sensitivity Cardiac Troponin Test |
— | — |
| SECONDARY Brain Natriuretic Peptide |
— | — |
Eligibility Criteria
Healthy children of healthcare professionals.
Exclusion Criteria
Not currently receiving antibiotics, not admitted to hospital within the last seven days, not receiving immunosuppressive drugs and never diagnosed with a malignancy.
Admitted children with paediatric multisystem inflammatory syndrome and admitted children with other serious infections.
Data sourced from ClinicalTrials.gov (NCT04347408). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.